The future of immunoglobulin therapy: An overview of the 2nd international workshop on natural antibodies in health and disease

Autoimmunity Reviews

Volumn 12, Issue 6, 2013, Pages 639-642

  Miescher, Sylvia M ^a   Käsermann, Fabian ^a  

^a ZLB Behring AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AUTOANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN FC FRAGMENT;

AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CATALYSIS; COMMON VARIABLE IMMUNODEFICIENCY; DOWN SYNDROME; DRUG EFFICACY; EDITORIAL; GENETIC ASSOCIATION; GLOMERULONEPHRITIS; HOMEOSTASIS; IMMUNOTHERAPY; INTESTINE MUCOSA; NONHUMAN; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN A;

EID: 84877062669     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.01.003     Document Type: Editorial

References (40)

1. Lutz H.U., Miescher S. Natural antibodies in health and disease: an overview of the first international workshop on natural antibodies in health and disease. Autoimmun Rev 2008, 7:405-409.
2. Bailey M., Christoforidou Z., Lewis M. Evolution of immune systems: Specificity and autoreactivity. Autoimmun Rev 2013, 12:643-647. (this issue).
3. Kaveri S.V. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 2012, 11:792-794.
4. Maddur M.S., Hegde P., Sharma M., Kaveri S.V., Bayry J. B cells are resistant to immunomodulation by 'IVIg-educated' dendritic cells. Autoimmun Rev 2011, 11:154-156.
5. Maddur M.S., Vani J., Hegde P., Lacroix-Desmazes S., Kaveri S.V., Bayry J. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 2011, 127:823-830.
6. Tha-In T., Bayry J., Metselaar H.J., Kaveri S.V., Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008, 29:608-615.
7. Kaveri S.V., Lacroix-Desmazes S., Bayry J. The antiinflammatory IgG. N Engl J Med 2008, 359:307-309.
8. Berger M. L-proline-stabilized human IgG: Privigen(R) 10% for intravenous use and Hizentra(R) 20% for subcutaneous use. Immunotherapy 2011, 3:163-176.
9. Danieli M.G., Pettinari L., Moretti R., Logullo F., Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011, 10:144-149.
10. Jolles S., Bernatowska E., de G.J., Borte M., Cristea V., Peter H.H., Belohradsky B.H., Neufang-Huber J., Zenker O., Grimbacher B. Efficacy and safety of Hizentra((R)) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 2011, 141:90-102.
11. Mahendra A., Sharma M., Rao D.N., Peyron I., Planchais C., Dimitrov J.D., Kaveri S.V., Lacroix-Desmazes S Antibody-mediated catalysis: Induction and therapeutic relevance. Autoimmun Rev 2013, 12:648-652. (this issue).
12. Djoumerska-Alexieva I., Pashova S., Vassilev T, Pashov A. The protective effect of modified intravenous immunoglobulin in LPS sepsis model is associated with an increased IRA B cells response. Autoimmun Rev 2013, 12:653-656. (this issue).
13. Dimitrov J.D., Roumenina L.T., Doltchinkova V.R., Mihaylova N.M., Lacroix-Desmazes S., Kaveri S.V., et al. Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions. J Biol Chem 2007, 282:26696-26706.
14. Pavlovic S., Zdravkovic N., Dimitrov J.D., Djukic A., Arsenijevic N., Vassilev T.L., et al. Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes. Clin Immunol 2011, 138:162-171.
15. Mihai S., Nimmerjahn F. The role of Fc receptors and complement in autoimmunity. Autoimmun Rev 2013, 12:657-660. (this issue).
16. Cousens L.P., Tassone R., Mazer B.D., Ramachandiran V., Scott D.W., De Groot A.S. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013, 12:436-443.
17. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673.
18. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320:373-376.
19. Kasermann F., Boerema D.J., Ruegsegger M., Hofmann A., Wymann S., Zuercher A.W., et al. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 2012, 7:e37243.
20. Guhr T., Bloem J., Derksen N.I., Wuhrer M., Koenderman A.H., Aalberse R.C., et al. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 2011, 6:e21246.
21. Leontyev D., Katsman Y., Ma X.Z., Miescher S., Kasermann F., Branch D.R. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 2012, 52:1799-1805.
22. Schwab I., Biburger M., Kronke G., Schett G., Nimmerjahn F. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol 2012, 42:826-830.
23. Leontyev D., Katsman Y., Branch D.R. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcgamma receptor for the amelioration of experimental ITP. Blood 2012, 119:5261-5264.
24. Corthesy B. Role of secretory IgA in infection and maintenance of homeostasis. Autoimmun Rev 2013, 12:661-665. (this issue).
25. Longet S., Miled S., Lotscher M., Miescher S.M., Zuercher A.W., Corthesy B. Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies. J Biol Chem 2013, 288:4085-4094.
26. Ben M.S., Rossato E., Heming N., Monteiro R.C. Anti-inflammatory role of the IgA Fc receptor (CD89): From autoimmunity to therapeutic perspectives. Autoimmun Rev 2013, 12:666-669. (this issue).
27. Brandao M., Marinho A. Idiopathic inflammatory myopathies: definition and management of refractory disease. Autoimmun Rev 2011, 10:720-724.
28. Kieseier B.C., Lehmann H.C., Meyer Zu H.G. Autoimmune diseases of the peripheral nervous system. Autoimmun Rev 2012, 11:191-195.
29. Lidar M., Langevitz P. Pregnancy issues in scleroderma. Autoimmun Rev 2012, 11:A515-A519.
30. Marie I. Therapy of polymyositis and dermatomyositis. Presse Med 2011, 40:e257-e270.
31. Rogosnitzky M., Danks R., Holt D. Intravenous immunoglobulin for the treatment of Crohn's disease. Autoimmun Rev 2012, 12:275-280.
32. Scoble T., Wijetilleka S., Khamashta M.A. Management of refractory anti-phospholipid syndrome. Autoimmun Rev 2011, 10:669-673.
33. Baerenwaldt A., Biburger M., Nimmerjahn F. Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol 2010, 6:425-434.
34. Imbach P., Lazarus A.H., Kuhne T. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang 2010, 98:385-394.
35. Tackenberg B., Nimmerjahn F., Lunemann J.D. Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. J Clin Immunol 2010, 30(Suppl. 1):S65-S69.
36. Weksler M.E., Szabo P., Relkin N.R., Reidenberg M.M., Weksler B.B., Coppus A.M. Alzheimer's disease and Down's syndrome: Treating two paths to dementia. Autoimmun Rev 2013, 12:670-673. (this issue).
37. Villeda S.A., Wyss-Coray T. The circulatory systemic environment as a modulator of neurogenesis and brain aging. Autoimmun Rev 2013, 12:674-677. (this issue).
38. Vincent A. Developments in autoimmune channelopathies. Autoimmun Rev 2013, 12:678-681. (this issue).
39. Goebel A., Blaes F. Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. Autoimmun Rev 2013, 12:682-686. (this issue).
40. Kellerl M.D., Jyonouchi S. Chipping away at a mountain: Genomic studies in common variable immunodeficiency. Autoimmun Rev 2013, 12:687-689. (this issue).